Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georgine E de Greef

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Current Opinion in Hematology|November 12, 2015
Plerixafor for stem cell mobilization: the current statusYavuz M Bilgin, Georgine E de Greef
British Journal of Haematology|April 10, 2015
Trends in incidence, primary treatment and survival in chronic myelomonocytic leukaemia: a population-based study of 1359 patients diagnosed in the Netherlands from 1989 to 2012Avinash G Dinmohamed, Mirian Brink, Otto Visser, et al.
British Journal of Haematology|January 11, 2005
Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studiesGeorgine E de Greef, Wim L J van Putten, Marc Boogaerts, et al.
Transfusion|December 15, 2018
The feasibility and efficacy of subcutaneous plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA-identical sibling donors: results of the HOVON-107 studyGeorgine E de Greef, Eric Braakman, Bronno van der Holt, et al.
Transfusion|February 3, 2015
Evaluation of Dutch guideline for just-in-time addition of plerixafor to stem cell mobilization in patients who fail with granulocyte-colony-stimulating factorYavuz M Bilgin, Otto Visser, Erik A M Beckers, et al.
British Journal of Haematology|July 26, 2002
Minimal residual disease quantification in patients with acute myeloid leukaemia and inv(16)/CBFB-MYH11 gene fusionBert A van der Reijden, Annet Simons, Erna Luiten, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2008
Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotypeDimitri A Breems, Wim L J Van Putten, Georgine E De Greef, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2005
Prognostic index for adult patients with acute myeloid leukemia in first relapseDimitri A Breems, Wim L J Van Putten, Peter C Huijgens, et al.
Leukemia Research|December 16, 2018
Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible?Rik A Brooimans, Vincent H J van der Velden, Nancy Boeckx, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2010
Low frequency of MLL-partial tandem duplications in paediatric acute myeloid leukaemia using MLPA as a novel DNA screenings techniqueBrian V Balgobind, Iris H I M Hollink, Dirk Reinhardt, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Current Opinion in Hematology|November 12, 2015
Plerixafor for stem cell mobilization: the current statusYavuz M Bilgin, Georgine E de Greef
British Journal of Haematology|April 10, 2015
Trends in incidence, primary treatment and survival in chronic myelomonocytic leukaemia: a population-based study of 1359 patients diagnosed in the Netherlands from 1989 to 2012Avinash G Dinmohamed, Mirian Brink, Otto Visser, et al.
British Journal of Haematology|January 11, 2005
Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studiesGeorgine E de Greef, Wim L J van Putten, Marc Boogaerts, et al.
Transfusion|December 15, 2018
The feasibility and efficacy of subcutaneous plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA-identical sibling donors: results of the HOVON-107 studyGeorgine E de Greef, Eric Braakman, Bronno van der Holt, et al.
Transfusion|February 3, 2015
Evaluation of Dutch guideline for just-in-time addition of plerixafor to stem cell mobilization in patients who fail with granulocyte-colony-stimulating factorYavuz M Bilgin, Otto Visser, Erik A M Beckers, et al.
British Journal of Haematology|July 26, 2002
Minimal residual disease quantification in patients with acute myeloid leukaemia and inv(16)/CBFB-MYH11 gene fusionBert A van der Reijden, Annet Simons, Erna Luiten, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2008
Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotypeDimitri A Breems, Wim L J Van Putten, Georgine E De Greef, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2005
Prognostic index for adult patients with acute myeloid leukemia in first relapseDimitri A Breems, Wim L J Van Putten, Peter C Huijgens, et al.
Leukemia Research|December 16, 2018
Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible?Rik A Brooimans, Vincent H J van der Velden, Nancy Boeckx, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2010
Low frequency of MLL-partial tandem duplications in paediatric acute myeloid leukaemia using MLPA as a novel DNA screenings techniqueBrian V Balgobind, Iris H I M Hollink, Dirk Reinhardt, et al.
Pageof 2